- Home
- UTMD
as of 03-11-2026 1:05pm EST
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | MIDVALE |
| Market Cap: | 196.4M | IPO Year: | 1994 |
| Target Price: | N/A | AVG Volume (30 days): | 9.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | 2.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $51.27 - $68.71 | Next Earning Date: | 04-30-2026 |
| Revenue: | $40,903,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | 23.79 | Index: | N/A |
| Free Cash Flow: | 14.6M | FCF Growth: | N/A |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 29, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYJan 29, 2026 · 100% conf.
1D
-0.40%
$61.40
Act: -1.13%
5D
+1.74%
$62.73
Act: +1.96%
20D
+1.62%
$62.65
Act: +9.25%
UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing
0000706698 false
0000706698
2026-01-29 2026-01-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 29, 2026
UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
UTAH
000-12575
87-0342734
(State or other jurisdiction of
(Commission File Number)
(IRS Employer
incorporation or organization)
Identification No.)
7043 South 300 West
Midvale, Utah
84047
(Address of principal executive offices)
(Zip code)
Registrant’s telephone number, including area code:
Phone: (801) 566-1200
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION
Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS
The following is filed as an exhibit to this report:
Exhibit
Number*
Title of Document
Location
Item 99.1
Financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026.
This filing
*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
Dated: January 29, 2026
By:
/s/ Kevin L. Cornwell
Kevin L. Cornwell, Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 23, 2025
Q3 2025 Earnings
8-KOct 23, 2025
UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing
0000706698 false
0000706698
2025-10-23 2025-10-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 23, 2025
UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
UTAH
000-12575
87-0342734
(State or other jurisdiction of
(Commission File Number)
(IRS Employer
incorporation or organization)
Identification No.)
7043 South 300 West
Midvale, Utah
84047
(Address of principal executive offices)
(Zip code)
Registrant’s telephone number, including area code:
Phone: (801) 566-1200
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION
Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated October 23, 2025.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS
The following is filed as an exhibit to this report:
Exhibit
Number*
Title of Document
Location
Item 99.1
Financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated October 23, 2025.
This filing
*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
Dated: October 23, 2025
By:
/s/ Kevin L. Cornwell
Kevin L. Cornwell, Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 24, 2025
Q2 2025 Earnings
8-KJul 24, 2025
UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing
0000706698 false
0000706698
2025-07-24 2025-07-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 24, 2025
UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
UTAH
000-12575
87-0342734
(State or other jurisdiction of
(Commission File Number)
(IRS Employer
incorporation or organization)
Identification No.)
7043 South 300 West
Midvale, Utah
84047
(Address of principal executive offices)
(Zip code)
Registrant’s telephone number, including area code:
Phone: (801) 566-1200
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION
Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated July 24, 2025.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS
The following is filed as an exhibit to this report:
Exhibit
Number*
Title of Document
Location
Item 99.1
Financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated July 24, 2025.
This filing
*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
Dated: July 24, 2025
By:
/s/ Kevin L. Cornwell
Kevin L. Cornwell, Chief Executive Officer
Compare UTMD vs Leading Stocks
See how UTMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "UTMD Utah Medical Products Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.